A PROSPECTIVE AND COMPARATIVE STUDY ON CONCURRENT RADIOTHERAPY WITH GEFITINIB VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF ELDERLY PATIENTS WITH CARCINOMA OESOPHAGUS

Authors

  • SUBHADIP BANDYOPADHYAY Superintendent, Panihati State General Hospital, Kolkata, West Bengal, India.
  • LINKON BISWAS Department of Radiotherapy, N R S Medical College, Kolkata, West Bengal, India. https://orcid.org/0000-0003-0589-769X
  • BISWARUP BANERJEE Department of Radiotherapy, N R S Medical College, Kolkata, West Bengal, India. https://orcid.org/0000-0002-4634-6176
  • Sumitava De Department of Radiotherapy, N R S Medical College, Kolkata, West Bengal, India. https://orcid.org/0000-0002-8263-5311
  • SRIKRISHNA MANDAL Department of Radiotherapy, N R S Medical College, Kolkata, West Bengal, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i7.44912

Keywords:

Carcinoma Esophagus, Gefitinib, Radiotherapy, Elderly patients

Abstract

Objective: Concurrent chemoradiotherapy (CTRT) is the primary treatment for inoperable carcinoma esophagus. However, elderly patients are often not capable of tolerating CTRT, leaving radiotherapy as only option available for them. Many studies showed efficacy of anti-EGFR agent Gefitinib with acceptable toxicity profile in carcinoma esophagus patients. Hence, in this study, we compared radiation along with Gefitinib against radiation alone for the treatment of inoperable esophageal carcinoma in elderly patients in terms of locoregional control and toxicity profile.

Methods: Patients of 50–70 years age group with inoperable squamous cell carcinoma esophagus were randomized in two groups – the control group received external beam radiotherapy 50.4 Gy in two phases over 5 weeks and the study group received radiotherapy with same dose along with Tab Gefitinib-250 mg daily during the radiotherapy. Response assessment was done after completion of treatment and all patients were followed up weekly during the course of treatment and then at every month for at least 6 months.

Results: Overall response rate (complete+partial response) was better in study arm (80% vs. 70%), but not statistically significant (p=0.221). Just after treatment completion dysphagia of grade2 and above was more in control arm but after 3 months there was rise in incidences of dysphagia in study arm (66.6% vs. 60% p=0.632). Although statistically not significant, gefitinib containing study arm showed more incidences of higher grade of diarrhoea (20% vs. 15%, p=0.843) and moderate to severe grade of anaemia (90% vs. 66%, p=0.921).

Conclusion: We can say that concomitant treatment with Gefitinib and radiotherapy was well tolerated and effective in elderly patients of inoperable carcinoma esophagus.

Downloads

Download data is not yet available.

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49. doi: 10.3322/caac.21660, PMID 33538338

Xu QL, Li H, Zhu YJ, Xu G. The treatments and postoperative complications of esophageal cancer: A review. J Cardiothorac Surg 2020;15:163. doi: 10.1186/s13019-020-01202-2, PMID 32631428

Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al- Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation therapy oncology group. JAMA 1999;281:1623-7. doi: 10.1001/jama.281.17.1623, PMID 10235156

Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123(Radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1164-74.

Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 2011;81:684-90. doi: 10.1016/j. ijrobp.2010.06.033, PMID 20932658

Xu Y, Xie Z, Shi Y, Zhang M, Pan J, Li Y, et al. Gefitinib single drug in treatment of advanced esophageal cancer. J Can Res Ther 2016;12:295-7.

Ferry DR, Anderson M, Beddard K, Tomlinson S, Atherfold P, Obszynska J, et al. A Phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: Evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007;13:5869-75. doi: 10.1158/1078-0432.CCR-06-1970, PMID 17908981

Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study. J Clin Oncol 1997;15:277-84. doi: 10.1200/ JCO.1997.15.1.277, PMID 8996153

Abedi-ardekani B, Dar NA, Mir MM, Zargar SA, Lone MM, Martel-Planche G, et al. Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia. BMC Cancer 2012;12:602. doi: 10.1186/1471-2407-12-602, PMID 23244191

Xu Y, Zheng Y, Sun X, Yu X, Gu J, Wu W, et al. Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study. Oncotarget 2015;6:38429-39. doi: 10.18632/oncotarget.5193, PMID 26392415

Published

07-07-2022

How to Cite

BANDYOPADHYAY, S., L. BISWAS, B. BANERJEE, S. De, and S. . MANDAL. “A PROSPECTIVE AND COMPARATIVE STUDY ON CONCURRENT RADIOTHERAPY WITH GEFITINIB VERSUS RADIOTHERAPY ALONE IN THE TREATMENT OF ELDERLY PATIENTS WITH CARCINOMA OESOPHAGUS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 15, no. 7, July 2022, pp. 144-8, doi:10.22159/ajpcr.2022.v15i7.44912.

Issue

Section

Original Article(s)